Combined antitumor activity of [<sup>177</sup>Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein.

EJNMMI Res · 2026 · PMC13069032 · PMID 41779297

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

While [ 177 Lu]Lu-FAP-2286 alone was sufficient to significantly inhibit tumor growth, the combination regimen showed a trend toward improved tumor growth control under the experimental conditions evaluated.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Combined antitumor activity of [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein.

The sentences

Combined antitumor activity of [<sup>177</sup>Lu]Lu-FAPI-2286 and pazopanib in a sarcoma model: a preclinical theranostic study targeting fibroblast activation protein.